The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Use of insulin-like growth factor (IGF) pathway polymorphism IGF1R_rs2016347 to predict tumor recurrence in estrogen receptor–positive breast cancer patients.
T. Winder
No relevant relationships to disclose
G. Giamas
No relevant relationships to disclose
W. Zhang
No relevant relationships to disclose
D. Yang
No relevant relationships to disclose
P. O. Bohanes
No relevant relationships to disclose
Y. Ning
No relevant relationships to disclose
A. Gerger
No relevant relationships to disclose
M. J. Labonte
No relevant relationships to disclose
J. Stebbing
No relevant relationships to disclose
H. Lenz
No relevant relationships to disclose